{"id":476388,"date":"2020-03-26T13:08:01","date_gmt":"2020-03-26T13:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476388"},"modified":"2020-03-26T13:08:01","modified_gmt":"2020-03-26T13:08:01","slug":"sanfilippo-syndrome-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sanfilippo-syndrome-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_476388.html","title":{"rendered":"Sanfilippo Syndrome Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Sanfilippo<\/a><\/div>\n

DelveInsight has launched a new report on Sanfilippo Syndrome Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Sanfilippo Syndrome – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Sanfilippo Syndrome, historical and forecasted epidemiology as well as the Sanfilippo Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Sanfilippo Syndrome market report provides current treatment practices, emerging drugs, Sanfilippo Syndrome market share of the individual therapies, current and forecasted Sanfilippo Syndrome market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Sanfilippo Syndrome treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Sanfilippo Syndrome, also known as Mucopolysaccharidosis type III (MPSIII), <\/strong>is a rare genetic condition that causes fatal brain damage. It is referred to as a childhood disease because most patients fail to reach adulthood. Sanfilippo is a metabolic disorder. One in 70,000 children is born with this inherited condition, which is caused by an enzyme deficiency. <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for<\/strong> :- <\/strong>sanfilippo syndrome free sample page<\/a><\/p>\n

Sanfilippo Syndrome Epidemiology  <\/strong><\/p>\n

The Sanfilippo Syndrome epidemiology division provide insights about historical and current Sanfilippo Syndrome patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  <\/p>\n

 Sanfilippo Syndrome Drug Chapters<\/strong><\/p>\n

Drug chapter segment of the Sanfilippo Syndrome report encloses the detailed analysis of Sanfilippo Syndrome marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Sanfilippo Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.<\/p>\n

Report Key facts:-<\/strong><\/p>\n

1. According to the National Organization for Rare Disorders<\/strong>, MPS III has been classified as a rare disease with incidence reported to be between 0.28 and 4.1 cases per 100,000 births.<\/p>\n

2. MPS IIIA is the most common subtype affecting around 1 in 100,000 births, closely followed by type B at 1 in 200,000. In some countries in Southern Europe, type B has been reported to be more common than A.<\/p>\n

3. MPS IIIC and IIID are rarer with reported incidences of approximately 1 in 1.5 million and 1 in 1 million births, respectively.<\/p>\n

“Sanfilippo affects mostly the Central Nervous System (CNS). Over time, brain cells fill up with waste that the body is unable to process”<\/em><\/p>\n

Key companies are working on Sanfilippo syndrome that are given below:-<\/strong><\/p>\n

1. <\/strong>Seelos Therapeutics<\/p>\n

2.Lysogene<\/p>\n

3. BioMarin Pharmaceutical<\/p>\n

Name of drugs covered are given below:- <\/strong><\/p>\n

1. SLS-005<\/p>\n

2. LYS-SAF302<\/p>\n

3.<\/strong> Tralesinidase alfa (BMN-250)<\/p>\n

 <\/p>\n

Table of Contents<\/a><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Sanfilippo Syndrome<\/span><\/p>\n

3. Competitive Intelligence Analysis for Sanfilippo Syndrome<\/span><\/p>\n

4. Sanfilippo Syndrome: Market Overview at a Glance<\/span><\/p>\n

4.1. Sanfilippo Syndrome Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Sanfilippo Syndrome Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Sanfilippo Syndrome: Disease Background and Overview<\/span><\/p>\n

6. Patient Journey<\/p>\n

7. Sanfilippo Syndrome Epidemiology and Patient Population<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Sanfilippo Syndrome Treatment and Management<\/span><\/p>\n

8.2. Sanfilippo Syndrome Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Sanfilippo Syndrome Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

12. Emerging Therapies<\/p>\n

13. Sanfilippo Syndrome: Seven Major Market Analysis<\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Sanfilippo Syndrome Market Size in 7MM<\/span><\/p>\n

13.3. Sanfilippo Syndrome Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

16. Access and Reimbursement Overview of Sanfilippo Syndrome<\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About <\/strong>DelveInsight<\/a><\/p>\n

Why should you buy this report?<\/strong><\/p>\n